1. Scrip
  2. >>Business
  3. >>Deals

AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

Deal May Indicate Renewed Pharma Appetite For Gene Therapy

 
• By Alaric DeArment

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Female eye with long eyelashes close up. Closeup shot of female gray - blue colour eye with day makeup. Beauty female eye with curl long eyelashes
Regenxbio stands to benefit from AbbVie's presence in eye care • Source: Shutterstock

Regenxbio Inc. will have sufficient resources to extend the global reach of RGX-314, its gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR), through a partnership with AbbVie Inc. worth potentially as much as $1.75bn. The company also stands to benefit from AbbVie’s expertise in eye diseases, without which the gene therapy maker may have found itself left to compete alone against other large drug makers in the space.

Rockville, MD-based Regenxbio and Chicago-based AbbVie said on 13 September that they entered into a development and commercialization deal, whereby...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

China Signals Restarting IPOs For Unprofitable Biotechs

 
• By Dexter Jie Yan

The China Securities Regulatory Commission has proposed a new “growth tier” for the STAR Market of the Shanghai Stock Exchange, to reinstate the market’s listing standards for unprofitable firms.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 
• By Mandy Jackson, Joseph Haas, and Sarah Karlin-Smith

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

Syncona Looks To Go Private As Market Decline Deepens

 
• By Andrew McConaghie

While some are calling for Syncona to be wound up, the UK-based company believes many existing and new investors will back the creation of new private fund.